Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Cytek Biosciences, Inc.
Report date June 10, 2026 · Filed June 12, 2026
Section 16 reporting ended · disclosed 2026-06-12. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 86,678 |
Reported balance
After 2026-06-10 transaction · row 1
1 source rowRow 1 · 2026-06-10 · Exercise / conversion · Acquired 43,973 · Balance 86,678 F1: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-06-10 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-10 · Exercise / conversion · Disposed 43,973 · Balance 0 F1: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F2: 100% of the shares subject to the RSU Award vested on June 10, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock.
F2: 100% of the shares subject to the RSU Award vested on June 10, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 10, 2026 Filed Jun 12, 2026 23:34 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionRestricted Stock Units · Derivative | 43,973 | $0.00 | $0.00 |
DisclosureSEC source: 0001873083-26-000001 · form4-06122026_110614.xml · derivative · entry 2 Ball Jack · CIK 0001873083 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 43,973 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: 100% of the shares subject to the RSU Award vested on June 10, 2026. F2 · derivative.expiration_date: 100% of the shares subject to the RSU Award vested on June 10, 2026. Read SEC document |
| June 10, 2026 Filed Jun 12, 2026 23:34 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionCommon Stock | 43,973 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001873083-26-000001 · form4-06122026_110614.xml · nonDerivative · entry 1 Ball Jack · CIK 0001873083 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 86,678 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| June 18, 2025 Filed Jun 20, 2025 20:20 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | GrantDirector Stock Option (right to buy) · Derivative | 23,809 | $0.00 Strike: $3.07 | $0.00 |
DisclosureSEC source: 0001415889-25-017844 · form4-06202025_080611.xml · derivative · entry 2 Ball Jack · CIK 0001873083 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,809 Underlying: Common Stock · 23,809 shares Expires 2035-06-18 F3 · derivative.exercise_date: 100% of the shares subject to the option shall vest on the earlier of June 18, 2026 and the date of the Issuer's 2026 annual meeting of stockholders (provided such meeting is held in June 2026). Read SEC document |
| June 18, 2025 Filed Jun 20, 2025 20:20 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | GrantRestricted Stock Units · Derivative | 43,973 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-017844 · form4-06202025_080611.xml · derivative · entry 1 Ball Jack · CIK 0001873083 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,973 Underlying: Common Stock · 43,973 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: 100% of the shares subject to the RSU Award shall vest on the earlier of June 18, 2026 and the date of the Issuer's 2026 annual meeting of stockholders (provided such meeting is held in June 2026). F2 · derivative.expiration_date: 100% of the shares subject to the RSU Award shall vest on the earlier of June 18, 2026 and the date of the Issuer's 2026 annual meeting of stockholders (provided such meeting is held in June 2026). Read SEC document |
| June 05, 2025 Filed Jun 9, 2025 21:04 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionRestricted Stock Units · Derivative | 15,706 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-016312 · form4-06092025_090659.xml · derivative · entry 2 Ball Jack · CIK 0001873083 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,706 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: 100% of the shares subject to the RSU Award vested on June 5, 2025. F2 · derivative.expiration_date: 100% of the shares subject to the RSU Award vested on June 5, 2025. Read SEC document |
| June 05, 2025 Filed Jun 9, 2025 21:04 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionCommon Stock | 15,706 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-016312 · form4-06092025_090659.xml · nonDerivative · entry 1 Ball Jack · CIK 0001873083 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,705 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| June 05, 2024 Filed Jun 7, 2024 23:03 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | GrantStock Option (right to buy) · Derivative | 23,076 | $0.00 Strike: $5.73 | $0.00 |
DisclosureSEC source: 0001415889-24-016081 · form4-06072024_110634.xml · derivative · entry 2 Ball Jack · CIK 0001873083 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,076 Underlying: Common Stock · 23,076 shares Expires 2034-06-05 Read SEC document |
| June 05, 2024 Filed Jun 7, 2024 23:03 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | GrantRestricted Stock Units · Derivative | 15,706 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-016081 · form4-06072024_110634.xml · derivative · entry 1 Ball Jack · CIK 0001873083 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,706 Underlying: Common Stock · 15,706 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: 100% of the shares subject to the RSU Award shall vest on June 5, 2025. F2 · derivative.expiration_date: 100% of the shares subject to the RSU Award shall vest on June 5, 2025. Read SEC document |
| June 14, 2023 Filed Jun 16, 2023 22:34 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | GrantStock Option (right to buy) · Derivative | 30,242 | $0.00 Strike: $8.38 | $0.00 |
DisclosureSEC source: 0001209191-23-038076 · doc4.xml · derivative · entry 1 Ball Jack · CIK 0001873083 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,242 Underlying: Common Stock · 30,242 shares Expires 2033-06-14 Read SEC document |
| November 29, 2022 Filed Dec 1, 2022 00:39 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionStock Option (Right to Buy) · Derivative | 13,333 | $0.00 Strike: $0.92 | $0.00 |
DisclosureSEC source: 0001209191-22-059113 · doc4.xml · derivative · entry 4 Ball Jack · CIK 0001873083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,333 shares Expires 2030-07-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The shares subject to the option vest as follows: 1/12th of the shares subject to the option shall vest monthly over one year from July 24, 2020. Read SEC document |
| November 29, 2022 Filed Dec 1, 2022 00:39 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,666 | $0.00 Strike: $0.40 | $0.00 |
DisclosureSEC source: 0001209191-22-059113 · doc4.xml · derivative · entry 3 Ball Jack · CIK 0001873083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,666 shares Expires 2028-10-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 29, 2022 Filed Dec 1, 2022 00:39 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionCommon Stock | 13,333 | $0.92 | $12,266.36 |
DisclosureSEC source: 0001209191-22-059113 · doc4.xml · nonDerivative · entry 2 Ball Jack · CIK 0001873083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,999 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 29, 2022 Filed Dec 1, 2022 00:39 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionCommon Stock | 10,666 | $0.40 | $4,266.40 |
DisclosureSEC source: 0001209191-22-059113 · doc4.xml · nonDerivative · entry 1 Ball Jack · CIK 0001873083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,666 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 14, 2022 Filed Nov 16, 2022 22:53 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionStock Option (Right to Buy) · Derivative | 16,000 | $0.00 Strike: $0.40 | $0.00 |
DisclosureSEC source: 0001209191-22-057368 · doc4.xml · derivative · entry 3 Ball Jack · CIK 0001873083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,666 Underlying: Common Stock · 16,000 shares Expires 2028-10-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 14, 2022 Filed Nov 16, 2022 22:53 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | SaleCommon Stock | 16,000 | $14.69 | $235,040.00 |
DisclosureSEC source: 0001209191-22-057368 · doc4.xml · nonDerivative · entry 2 Ball Jack · CIK 0001873083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 12, 2022. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.53 to $14.93, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| November 14, 2022 Filed Nov 16, 2022 22:53 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionCommon Stock | 16,000 | $0.40 | $6,400.00 |
DisclosureSEC source: 0001209191-22-057368 · doc4.xml · nonDerivative · entry 1 Ball Jack · CIK 0001873083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 01, 2022 Filed Jun 3, 2022 21:38 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | GrantStock Option (right to buy) · Derivative | 25,789 | $0.00 Strike: $9.67 | $0.00 |
DisclosureSEC source: 0001209191-22-034261 · doc4.xml · derivative · entry 1 Ball Jack · CIK 0001873083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,789 Underlying: Common Stock · 25,789 shares Expires 2032-06-01 Read SEC document |
| July 22, 2021 Filed Jul 28, 2021 01:03 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | PurchaseCommon Stock | 3,000 | $17.00 | $51,000.00 |
DisclosureSEC source: 0001209191-21-048388 · doc4.xml · nonDerivative · entry 1 Ball Jack · CIK 0001873083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 F1 · shares: Reflects shares purchased from the underwriters in the Company's initial public offering. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.